Shapiro David 4

What Happened
David Shapiro, a director of Design Therapeutics (DSGN), received two grants of derivative awards on March 31, 2026: 60,000 shares and 7,500 shares, each reported at $0.00 per share (total reported value $0). These awards are reported as grants (transaction code A) and will vest over time per the schedules below.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 1, 2026 (timely filing).
• Grants: 60,000 derivative shares @ $0.00 and 7,500 derivative shares @ $0.00 (total 67,500).
• Vesting: 60,000 shares vest in equal monthly installments over 36 months beginning March 31, 2026 (F1); 7,500 shares vest in equal monthly installments over 12 months beginning March 31, 2026 (F2).
• Shares owned after the transaction: not specified in this Form 4.
• No cash paid or sale reported; these are awards/derivative grants (code A), not open‑market purchases or exercises.

Context
These grants are time‑based awards that give the director a right to receive company shares as they vest; they do not represent an immediate purchase or sale and do not indicate any immediate cash change. For retail investors, awards signal retention/compensation actions rather than direct insider buying/selling.